Evidence map›Paper›PMID 36744986›Full record

ArticleCurrent protocols2023

Murine-Derived Glioma Organoids and Cell Line Culture Systems.

Alberto E Ayala-Sarmiento, David Rincon Fernandez Pacheco, Joshua J Breunig

Abstract read
In one paragraph

Article in Current protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alberto E Ayala-SarmientoBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California.
David Rincon Fernandez PachecoBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Joshua J BreunigBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Radiation-induced vascular reprogramming in glioblastomaR01NS121617 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HARLEY IAN KORNBLUM · 2022 to 2026
$2.3M
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic DriversR33CA202900 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BREUNIG, JOSHUA JOHN · 2016 to 2018
$1.2M
GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor ModelsR33CA236687 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BREUNIG, JOSHUA JOHN · 2019 to 2021
$1.2M
Direct Differentiations of iPSCs: an Autologous and Scalable Source of Striatal Medium Spiny Neurons for Cellular Transplantation TherapyR03NS101529 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI BREUNIG, JOSHUA JOHN · 2017 to 2018
$175k
NCI NIH HHS P50 CA211015NCI NIH HHS R33 CA202900NCI NIH HHS R33 CA236687NINDS NIH HHS R01 NS121617NINDS NIH HHS R03 NS101529
6 · The paper itself

Abstract

Research models in cancer have greatly evolved in the last decade, with the advent of several new methods both in vitro and in vivo. While in vivo models remain the gold standard for preclinical studies, these methods present a series of disadvantages such as a high cost and long periods of time to produce results compared with in vitro models. We have previously developed a method named Mosaic Analysis by Dual Recombinase-mediated cassette exchange (MADR) that generates autochthonous gliomas in immunocompetent mice through the transgenesis of personalized driver mutations, which highly mimic the spatial and temporal tumor development of their human counterparts. Due to the control of single-copy expression of transgenes, it allows for comparing the visualization of tumor cells and non-tumor cells. Here we describe a method to generate murine-derived glioma organoids (MGOs) and cell line cultures from these murine models by physical and enzymatic methods for in vitro downstream applications. Tumor cells can be readily distinguished from non-tumor cell populations, in both organoids and monolayer cell cultures, and isolated due to the use of personalized fluorescent reporter transgenes. © 2023 Wiley Periodicals LLC. Basic Protocol 1: Generation of 3D murine-derived glioma organoids Basic Protocol 2: Generation of 2D glioma monolayer cell lines.

Indexed as

GliomaAnimalsCell Culture TechniquesCell LineHumansMiceOrganoidsTransgenesbiobankgliomaMADRorganoidspersonalized driver mutations

Identifiers

PMID36744986
PMCPMC9909623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.